Certara adds four new global leaders.

Byline: Anthony Vecchione

Princeton-based Certara, a drug development, regulatory science, real-world evidence and market access services company, announced on Wednesday four senior executive appointments in its Simcyp division.

Simcyp is a provider of mechanistic modeling technologies used to inform drug development, including physiologically based pharmacokinetic (PBPK), quantitative systems pharmacology (QSP) and quantitative systems toxicology and safety (QSTS) approaches. For example, the Simcyp Simulator has been used to inform 50 novel drug applications, including more than 200 label claims made without the need for clinical trials.

Rob Aspbury, joins Simcyp as chief executive officer; Frederic Yves Bois, is the division's new senior scientific advisor and head of mechanistic modeling; Will Redfern, is vice president, Quantitative Systems Toxicology and Safety; and Noriko Okudaira, is senior consultant/scientific advisor supporting Certara's clients locally in Japan.

"I am delighted to welcome Rob, Frederic, Will and Noriko to the Simcyp team. It is a testament to the major scientific and technological advances that Simcyp continues to make that we are able to attract staff of this caliber," said Steve Toon, Simcyp president and managing director. "Focusing on safety and efficacy, the team will build on Simcyp's position, delivering confidence in drug...